MedPath

Treatment of Nidranasha by Jatamansi Churna and Nirgundi Taila Padabhyanga

Phase 1
Not yet recruiting
Conditions
Factors influencing health status and contact with health services. Ayurveda Condition: NIDRANASAH/ASVAPNAH,
Registration Number
CTRI/2022/11/047445
Lead Sponsor
Manasi Pradhan
Brief Summary

This is a study on Nidra and evaluation of the effect of Jatamansi Churna and Nirgundi Taila Padabhyanga in Nidranasha. This is done compulsory part of Post Graduate Course. Total No. of patients to be studied is 40 with duration of 15 days

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria
  • 1.Patients having Nidranasha as per clinical sign and symptoms as in classical text.
  • 2.Patients of both the sex in the age between 30-70 yrs.
  • 3.Patients without any systemic disorders.
  • 4.Patient is having difficulty in initiating sleep even after one hour.
Exclusion Criteria
  • 1.Patients suffering from other systemic illness and metabolic disorders.
  • 2.Patients of both sex in the age below 30 and above 70 years.
  • 3.Patient who are on psychiatric treatment.
  • 4.Accident cases, post-operative cases, drug abuser, alcohol addicted, mentally retarded and psychiatric abnormalities, pregnant and lactating mother.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To control the symptoms of Nidranasha by the internal application of Jatamansi Churna.15 Days
Secondary Outcome Measures
NameTimeMethod
Internal application Jatamansi Churna and Nirgundi Taila Padabhyanga are more effective than the internal application of Jatamansi Churna in Nidranasha.15 Days

Trial Locations

Locations (1)

Govt Ayurvedic College and Hospital Balangir

🇮🇳

Balangir, ORISSA, India

Govt Ayurvedic College and Hospital Balangir
🇮🇳Balangir, ORISSA, India
Prof Dr Arun Ku Das
Principal investigator
9861229623
dasarun1969@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.